| Market Capitalization (Millions $) |
603 |
| Shares
Outstanding (Millions) |
29 |
| Employees |
164 |
| Revenues (TTM) (Millions $) |
332 |
| Net Income (TTM) (Millions $) |
40 |
| Cash Flow (TTM) (Millions $) |
21 |
| Capital Exp. (TTM) (Millions $) |
28 |
Castle Biosciences Inc
Castle Biosciences Inc is a medical technology company that specializes in molecular diagnostics for skin cancer. The company is based in Friendswood, Texas, and was founded in 2008 by Derek Maetzold, James Patterson and Federico Monsonego.
Castle Biosciencese mission is to improve patientse lives through the development of highly accurate and clinically actionable diagnostics for challenging cancer types. The company focuses on developing and commercializing genomic-based diagnostic tests that provide physicians and patients with accurate information to help identify the most effective treatment options.
The companyes flagship diagnostic test is DecisionDxe-Melanoma, a gene expression profile test that provides an individualized risk assessment for patients with cutaneous melanoma. The test is designed to help physicians determine which patients are at high risk of recurrence and who would benefit from closer surveillance and more aggressive treatment.
In addition to DecisionDxe-Melanoma, Castle Biosciences has developed diagnostic tests for uveal melanoma, cutaneous squamous cell carcinoma, and other cancers. The company also offers a suite of testing services for physicians, including gene expression profiling, next-generation sequencing, and pathology services.
Castle Biosciences has a robust research and development program, with a team of scientists and bioinformaticians working to identify new biomarkers and diagnostic tests for other types of cancer. The company is committed to advancing precision medicine by integrating genomic tools into clinical practice and providing patients with individualized treatment options based on their genetic profile.
The company has been recognized for its innovative work in cancer diagnostics, receiving the 2020 Clinical Diagnostics Company of the Year award from Frost & Sullivan. Castle Biosciences also recently went public in 2019 and is traded on the NASDAQ under the ticker eCSTLe.
Overall, Castle Biosciences Inc is a leading medical technology company that is helping to advance the field of precision medicine by developing highly accurate and clinically actionable diagnostics for challenging cancer types.
Company Address: 505 S. Friendswood Drive Friendswood 77546 TX
Company Phone Number: 788-9007 Stock Exchange / Ticker: NASDAQ CSTL
|
75.84 %